Clinical research

Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial

EuroIntervention 2014;10:58-64 published online ahead of print April 2014. DOI: 10.4244/EIJV10I1A11

Sune Haahr Pedersen
Sune Haahr Pedersen1*, MD, PhD; Matthias Pfisterer2, MD; Christoph Kaiser2, MD, DmSc; Jan Skov Jensen1, MD, PhD, DmSc; Hannes Alber3, MD; Peter Rickenbacher4, MD; Rikke Sørensen1, MD, PhD; Allan Iversen1, MD, PhD; Magnus Thorsten Jensen1, MD; Kim Wadt1, MD; Søren Galatius1, MD, DmSc; for the BASKET-PROVE Investigators
1. Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark; 2. Department of Cardiology, University Hospital, Basel, Switzerland; 3. Department of Cardiology, University Hospital, Innsbruck, Austria; 4. Department of Cardiology, Univ

Aims: The use of drug-eluting stents (DES) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is controversial and not yet endorsed in clinical guidelines.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

bare metal stentclinical researchguidelinesnon-st-segment elevation acute coronary syndromeoutcomerandomised controlled trial
Read next article
Validation of residual SYNTAX score with second-generation drug-eluting stents: one-year results from the prospective multicentre SEEDS study

Latest news